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Introduction: Current medical treatment for individuals diagnosed with schizophrenia (SCHZ) 
primarily relies on the inhibition of the dopamine D2 receptor that has been shown to be 
supersensitive in these patients. Treatment occurs through the use of antipsychotic medication 
which leads to a number of debilitating dose-dependent side effects, such as weight gain, 
agranulocytosis, and seizures. Patients diagnosed with SCHZ have also been shown to have 
increased inflammation in their central nervous system (CNS), particularly within specific brain 
regions such as the prefrontal cortex and hippocampus. This is in large part due to the 
interaction between a pro-inflammatory cytokine called tumor necrosis factor-alpha (TNFα) and 
microglia, which are resident CNS defense cells. TNFα is a cell-signaling protein, regulates a 
variety of immune cells, and is involved in the acute phase reaction of inflammation. Upon 
activation by TNFα secretion, microglial cells switch from being anti-inflammatory (M2) to pro-
inflammatory (M1), thereby resulting in neuroinflammation as well as synaptic loss and 
neuronal death. In this project, we hypothesized oral administration through the diet of a novel 
TNFα modulator (PD2024) developed by P2D Biosciences, Inc. (Cincinnati, OH) would 
significantly reduce microglia activation in rats neonatally treated with Polyinosinic:polycytidylic 
acid (poly I:C). Methods and Results: To test our hypothesis, four groups (Neonatal Poly 
I:C/TNFα, Neonatal Poly I:C/Control, Neonatal Saline/TNFα, and Neonatal Saline/Control) 
were intraperitoneally injected with either poly I:C or saline during postnatal days (P)5-7. Poly 
I:C is an immunostimulant that mimics neonatal infection in humans, which also has been 
found to be a factor for the development of SCHZ later in life. Between days (P)30-(P)60, the 
Neonatal Poly I:C/TNFα and Neonatal Saline/TNFα groups were orally administered PD2024 
through the diet. After (P)60, brain tissue was evaluated by immunohistochemistry (IHC) and 
confocal microscopy. Immunohistochemistry was used to label microglial cells in the prefrontal 
cortex and hippocampus with a green fluorescent dye attached to Iba1, a protein that 
specifically binds to these cells. Upon completion of IHC, tissue was evaluated using a 
confocal microscope and then analyzed with NIH ImageJ software. Analysis parameters 
included cell count, sampled cell body fluorescence, and overall image fluorescence. The 
results obtained showed a significant decrease in microglia activation for the Poly I:C/TNFα
group when compared to the Poly I:C/Control group, as well as similarities in activation levels 
with the Saline/Control group. These results were demonstrated in both sampled cell body 
fluorescence and overall image fluorescence measurements. Conclusion: This data supports 
the hypothesis that PD2024 is successful in reducing microglia activation through the 
modulation of TNFα. Therefore, treatment with a TNFα modulator such as PD2024 alongside 
of current antipsychotic medication could mediate neuroinflammation and reduce the dose-
dependent side effects. This approach could be a promising therapeutic treatment option for 
those diagnosed with schizophrenia, as well as potentially for other neurocognitive and 
behavioral disorders. 
Methods
Figure 3. Sampled Cell Body Fluorescence
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Neonatal Poly I:C Treatment (P5-7)
• Animals were intraperitoneally (IP) administered either poly I:C (2 mg/kg) or saline during 
postnatal days 5-7. 
Dietary Treatment
• All animals were given food ad libitum.
• Animals in the Neonatal Poly I:C/TNFα and Neonatal Saline/TNFα were given a chow that 
contained PD2024 between P30-P60.
• Animals in the remaining two groups (Poly IC Control and  Saline Control) were given a 
chow that did not contain the drug. 
• The two chows were identical up to P30 and did not contain any additional additives. 
Immunohistochemistry (IHC) 
• Formalin fixed, cryopreserved brain tissues were coronally sectioned on a Leica cryostat at 
50 μm thickness and stored at -20ºC until immunolabeling.
• Iba1 (Wako Chemicals USA, Richmond, VA) was the primary antibody used for IHC labeling 
of microglial cells and AlexaFluor488 conjugated Anti-Rabbit IgG (Jackson 
ImmunoResearch Laboratories, West Grove, PA) was the secondary antibody tagged with 
GFP to emit fluorescence.
• Free floating sections were mounted on glass slides and coverslipped using mounting 
media.
• Slides were examined under a Leica TCS SP8 inverted confocal microscope at a 
magnification of 40x.
• 4 images were captured per brain region (4 pFC, 2 CA1 & 2 CA3 of the Hip)
Image Analysis and Quantification 
• NIH ImageJ software was used to quantify images of the prefrontal cortex and CA1 and CA3 
regions of the dorsal hippocampus. 
• Measurements and quantification included manual cell count, average sampled cell body 
fluorescence, and overall field fluorescence.
• Cell count per given field was measured using two different experimenters who were blind to 
all conditions. 
• The freehand tool in ImageJ was used to draw around a given microglia cell body.
• Integrated Density from ImageJ was used to determine average cell body fluorescence and 
overall field fluorescence. 
• At random, five GFP-stained microglia cells were selected per given field for the 
measurement of average cell body fluorescence. 
Statistical Analysis
• A separate one-way ANOVA was used to analyze each brain area.
• The Newman-Keuls post hoc test (p=0.05) was used to analyze significant interactions 
(p=0.05).
Purpose & Hypotheses
• Schizophrenia (SCHZ) is a chronic debilitating neurocognitive and behavioral disorder that 
affects approximately 21 million people worldwide [1].
• Current medical treatment relies on the modulation of the dopamine D2 receptor, shown to 
have supersensitivity in those diagnosed with SCHZ [2-4].
• Treatment to modulate this receptor through the use of typical and atypical antipsychotic 
medications has a number of debilitating dose-dependent side effects, including insulin 
resistance/diabetes, agranulocytosis, and seizures [5].
• Increasing evidence suggests neuroinflammation in humans plays a significant 
pathophysiological role in SCHZ [6-7].
• Individuals diagnosed with SCHZ have higher levels of inflammation in their CNS, 
particularly within specific brain regions, such as the prefrontal cortex (pFC) and 
hippocampus (Hip) [8].
• Rats injected with polyinosinic:polycytidylic acid (poly I:C) between postnatal days 5-7 
show increased neuroinflammation during lifespan, consistent with SCHZ [9].
• This study investigates the use of a novel anti-inflammatory compound produced by our 
collaborators at P2D Bioscience, Inc. (Cincinnati, OH) to reduce neuroinflammation via 
microglial cell quantification in rats neonatally treated with poly I:C. 
The central aim of this study was to determine if treatment with an anti-inflammatory 
compound (PD2024 – TNFα modulator) can reduce microglia activation 
(neuroinflammation) in rats neonatally treated with poly I:C.
Hypotheses:
1. Neonatal poly I:C will result in increased microglial activation.
2. Neuroinflammation in the pFC and Hip as a result of neonatal poly I:C  
treatment will be attenuated by oral administration of PD2024.
3. Reduction in neuroinflammatory levels will be similar to control levels.
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Figure 1. Prefrontal Cortex IHC Analysis
• Across all three brain areas, the Poly IC Control demonstrated 
increased microglia cell body fluorescence intensity (*p<.05).
• Regardless of the brain area, rats administered PD2024 
through the diet had decreased microglia activation levels 
similar to the saline controls.
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• Treatment with poly I:C activates the neuroinflammatory 
response, indicated by elevated microglia levels.
• PD2024 is effective in reducing microglia activation through 
the modulation of TNFα.
• PD2024 treatment was similar to the control group 
(Neonatal Saline/Control).
• TNFα modulation could reduce the dose-dependent side 
effects observed with current antipsychotic medication and 
modulate the neuroinflammation in those diagnosed with 
SCHZ.
• Future studies will examine additional TNFα modulators 
produced by collaborators at P2D Bioscience, Inc. 
(Cincinnati, OH) to determine efficacy across multiple 
compounds in the Poly I:C model of schizophrenia. 
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